title: The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
abstract: Glucagon-like peptide-1 (GLP-1) is the main member of the incretin family and stimulates insulin secretion by binding with its specific receptor on pancreatic β-cells. In addition, GLP-1 exerts broad beneficial effects on the glucose regulation by suppressing food intake and delaying stomach emptying. Now, long acting GLP-1 analogs including exenatide and liraglutide have been approved for the treatment of diabetes mellitus type 2, however long-term injection can limit their use for these chronic patients. In this report, the authors provide a review on the development of non-peptide GLP-1 receptor agonists and introduce a novel agonist DA-15864.
authors.affiliation: Research Center, Dong-A Pharm. Co., Ltd., Yongin 446-905, Korea. ssonmh@donga.co.kr
authors.forename: Ho-Sang
authors.initials: HS
authors.lastname: Moon
authors.forename: Mi-Kyung
authors.initials: MK
authors.lastname: Kim
authors.forename: Moon-Ho
authors.initials: MH
authors.lastname: Son
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D015195:Drug Design; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000096:biosynthesis; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000502:physiology; D058990:Molecular Targeted Therapy; D051381:Rats; D018027:Receptors, Glucagon / Q000819:agonists* / Q000378:metabolism
chemical_list: C000593833:GLP1R protein, human; C000593835:Glp1r protein, rat; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D007328:Insulin; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1